KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Inventory (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Change in Inventory data on record, last reported at $4.9 million in Q4 2025.

  • For Q4 2025, Change in Inventory rose 10.58% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $18.2 million, down 63.28%, while the annual FY2025 figure was $18.2 million, 63.28% down from the prior year.
  • Change in Inventory reached $4.9 million in Q4 2025 per ACAD's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $27.1 million in Q2 2024 and bottomed at -$1.2 million in Q3 2025.
  • Average Change in Inventory over 5 years is $4.9 million, with a median of $2.2 million recorded in 2023.
  • Peak YoY movement for Change in Inventory: tumbled 269.31% in 2022, then soared 4960.32% in 2023.
  • A 5-year view of Change in Inventory shows it stood at -$217000.0 in 2021, then tumbled by 42.86% to -$310000.0 in 2022, then skyrocketed by 4960.32% to $15.1 million in 2023, then tumbled by 70.64% to $4.4 million in 2024, then increased by 10.58% to $4.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $4.9 million in Q4 2025, -$1.2 million in Q3 2025, and $4.1 million in Q2 2025.